These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience]. Roth J; Růzicka E; Mecír P Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. Ray-Chaudhuri K; Abbott RJ; Millac PA J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):372-3. PubMed ID: 2056329 [No Abstract] [Full Text] [Related]
11. [The diagnosis of the parkinsonian syndrome]. Möller JC; Pogarell O; Oertel WH Dtsch Med Wochenschr; 1999 Feb; 124(7):193-6. PubMed ID: 10093579 [No Abstract] [Full Text] [Related]
12. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277 [TBL] [Abstract][Full Text] [Related]
13. Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease. Grandas F; Gancher S; Lera G; Rodriguez M; Woodward WR; Nutt J; Obeso JA Neurology; 1992 Jul; 42(7):1287-90. PubMed ID: 1620335 [TBL] [Abstract][Full Text] [Related]
14. The motor response to sequential apomorphine in parkinsonian fluctuations. Hughes AJ; Lees AJ; Stern GM J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323 [TBL] [Abstract][Full Text] [Related]
15. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061 [TBL] [Abstract][Full Text] [Related]
16. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Stibe C; Lees A; Stern G Lancet; 1987 Apr; 1(8537):871. PubMed ID: 2882282 [No Abstract] [Full Text] [Related]
17. Apomorphine in patients with Parkinson's disease. Muguet D; Broussolle E; Chazot G Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939 [TBL] [Abstract][Full Text] [Related]
18. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease. Papuć E; Trzciniecka O; Rejdak K Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043 [TBL] [Abstract][Full Text] [Related]
19. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Garcia Ruiz PJ Mov Disord; 2006 May; 21(5):727-8. PubMed ID: 16547919 [No Abstract] [Full Text] [Related]